Erratum: Efficacy and safety of oral candesartan cilexetil in patients with congestive heart failure (European Journal of Heart Failure (2003) 5 (699-677) DOI: 10.1016/S1388-9842(03)00162-4);Efficacy and safety of oral candesartan cilexetil in patients with congestive heart failure

European Journal of Heart Failure

Volumn 5, Issue 5, 2003, Pages 669-677

  Matsumori, Akira ^a  

^a KYOTO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Candesartan cilexetil; Congestive heart failure; Randomised study; RAS inhibition

Indexed keywords

ANGIOTENSIN RECEPTOR; ANTIARRHYTHMIC AGENT; BENZIMIDAZOLE DERIVATIVE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BIPHENYL DERIVATIVE; CANDESARTAN HEXETIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; INOTROPIC AGENT; PLACEBO;

ADULT; AGED; ARTICLE; CARDIOVASCULAR SYMPTOM; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; DISEASE SEVERITY; DIZZINESS; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HEART LEFT VENTRICLE FUNCTION; HEMODYNAMICS; HUMAN; HYPOTENSION; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK REDUCTION; SIDE EFFECT; TIME; TREATMENT OUTCOME;

EID: 0345923833     PISSN: 13889842     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejheart.2004.05.001     Document Type: Erratum

References (20)

1. Williams JF, Bristow MR, Fowler MB, et al. Guidelines for the evaluation and management of heart failure. Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Evaluation and Management of Heart Failure). Circulation 1995;92:2764-2784.
2. Pitt B, Zannad F, Remme WJ, et al. Randomised aldactone evaluation study investigators. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 1999;341:709-17.
3. Zannad F, Briancon S, Juilliere Y, et al. Incidence, clinical and etiologic features and outcomes of advanced chronic heart failure: the EPICAL Study. J Am Coll Cardiol 1999;33:734-42 (and the EPICAL Investigators).
4. Packer M, Cohn J. Consensus recommendations for the management of chronic heart failure. Am J Cardiol 1999;83:1A-38A (On behalf of the steering committee and membership of the advisory council to improve outcomes nationwide in heart failure).
5. O'Connell JB, Bristow M. Economic impact of heart failure in the United States: time for a different approach. J Heart Lung Transplant 1993;13:S107-S112.
6. Consensus Trial Study Group. Effect of enalapril on mortality in severe heart failure. N Engl J Med 1987;316:1429-35.
7. SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991;325:295-302.
8. Pfeffer MA, Braunwald E, Moye LA, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. N Engl J Med 1992;327:669-77.
9. Riegger GA, Bouzo H, Petr P, et al. Symptom, tolerability, response to exercise trial of candesartan cilexetil in heart failure (STRETCH) investigators. Improvement in exercise tolerance and symptoms of congestive heart failure during treatment with candesartan cilexetil. Circulation 1999;100:2224-30.
10. International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use. Statistical principles for clinical trials. Stat Med, 1999;18:1905-1942.
11. Armstrong PW, Moe GW. Medical advances in the treatment of congestive heart failure. Circulation 1994;88:2941-52.
12. Brown NJ, Vaughan DE. Angiotensin-converting enzyme inhibitors. Circulation 1998;97:1411-20.
13. Baruch L, Anand I, Cohen IS, Ziesche S, Judd D, Cohn JN. Vasodilator heart failure trial (V-HeFT) study group. Augmented short- and long-term hemodynamic and hormonal effects of an angiotensin receptor blocker added to angiotensin converting enzyme inhibitor therapy in patients with heart failure. Circulation 1999;99:2658-64.
14. Meredith P. Achieving quality 24-h blood pressure control with candesartan cilexetil. Blood Pressure 2000;1(Suppl.):23-6.
15. Granger CB, Ertl G, Kuch J, et al. Randomised trial of candesartan cilexetil in the treatment of patients with congestive heart failure and a history of intolerance to angiotensin-converting enzyme inhibitors. Am Heart J 2000;139:609-17.
16. McKelvie RS, Yusuf S, Pericak D, et al. Comparison of candesartan, enalapril and their combination in congestive heart failure: randomised evaluation of strategies for left ventricular dysfunction (RESOLVD) pilot study: the RESOLVD pilot study investigators. Circulation 1999;100:1056-64.
17. Cohn JN, Tognoni G. Valsartan heart failure trial investigators. A randomised trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 2001;345:1667-75.
18. McMurray JJ. Angiotensin receptor blockers for chronic heart failure and acute myocardial infarction. Heart 2001;86:97-103.
19. Berry C, Norrie J, McMurray JJ. Are angiotensin II receptor blockers more efficacious than placebo in heart failure? Implications of ELITE-2. Evaluation of losartan in the elderly. Am J Cardiol 2001;87:606-7 (A9).
20. Swedberg K, Pfeffer M, Granger C, et al. Candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM): rationale and design. Charm-programme investigators. J Card Fail 1999;5:276-82.